Background: Lactic acidosis (LA) and severe hyperlactataemia (HL) are infrequent but serious complications of antiretroviral therapy that have been associated with a high fatality rate. Methods: In a multinational retrospective cohort study, LA was defined as arterial blood pH<7.35, bicarbonate <20 mmol/l and lactate above normal, and HL as confirmed blood lactate >5 mmol/l. Logistic regression was used to identify factors associated with fatality. Sensitivity and specificity of different case definitions as predictors of death were compared. Results: The overall case-fatality rate was 19/110 (17.3%), but among acidotic patients it was 33% (16/49 cases). There were 10 asymptomatic patients and none of them died as a consequence of the event. The median lactate for fatal, non-fatal and all patients was 8.3 mmol/l (IQR 7.2-13.1), 6.4 mmol/l (IQR 5.4-7.8) and 6.7 mmol/l (IQR 5.5-8.1), respectively. After adjusting for age and current CD4 + T-cell count, lactate >7 mmol/l (OR 6.27, 95% CI 1.13-34.93), blood bicarbonate <12 mmol/l (OR 10.02 relative to >18 mmol/l, 95% CI 1.33-75.65) and concurrent opportunistic infections (OR 8.69, 95% CI 1.45-52.22) were independently associated with case fatality. Blood lactate >7 mmol/l showed a sensitivity of 84% for fatality with a specificity of 60%, whereas bicarbonate <12 mmol/l showed a better specificity (85%) but a poorer sensitivity (42%). Bicarbonate <18 mmol/l appears to be as good as lactate <7 mmol/l at predicting death (sensitivity 90% and specificity 54%). Conclusions: Our data suggest that blood lactate >7 mmol/l and blood bicarbonate <18 mmol/l appear to predict death and might help clinicians in selecting patients who may benefit from more intense monitoring.
Introduction
reported number of adverse reactions attributable to dideoxynucleosides [2, 3] . Incidence rates of HL/LA in South Africa have been reported as ranging from 10-19 cases per 1,000 person-years on ART [2, 4, 5] versus 0.8-8.7 cases per 1,000 person-years on ART in well-resourced countries [6] . This apparent higher incidence of HL/LA in resource-limited countries might mainly be because stavudine is often part of the first-line combination therapy available in most countries. However, previously reported risk factors for HL/LA, such as female gender and advanced HIVinduced immunosuppression, are also more frequent in resource-limited settings [3, 7] .
Another factor that may explain in part the differences in incidence of HL/LA between studies is the lack of a universally accepted case definition for hyperlactataemic conditions in HIV-infected patients. Most case definitions proposed combine the presence of symptoms along with abnormal blood lactate levels to make a diagnosis [8] [9] [10] .
Although previous case-series and observational studies have shown fatality rates ranging between 15-60% [11] [12] [13] [14] , little is known about specific risk factors for fatality among patients with HL/LA. Observational studies have found blood lactate levels >10 mmol/l and low bicarbonate levels to be associated with fatal outcome in patients with HL/LA [5, 13, 15] .
Previously, in a large multinational case-control study, we examined the risk factors for HL/LA. No analyses of the risk factors associated with mortality were performed [16] . The aim of this study was to identify factors associated with a fatal outcome in the same study population.
Methods
All participants who met the criteria for HL/LA in our multinational case-control study to identify risk factors for these complications in HIV-infected adults exposed to ART [16] were included in this retrospective cohort analysis. In the parent study, severe HL was defined as confirmed blood lactate >5 mmol/l, and LA as blood pH<7.35, bicarbonate <20 mmol/l and lactate above normal range. Arterial gases, pH and bicarbonate were not measured in all patients with HL.
The aim of the present analysis was to identify factors associated with fatality by comparing patients that died as a consequence of the event to patients who survived it. Demographics, clinical data on HIV infection, full ART exposure history, and acid-base balance and blood lactate laboratory values at the time of event diagnosis were recorded. Information on previous or concurrent ART-induced adverse reaction was also collected. Body mass index was not included in the analysis because data on height of most patients was not available.
Statistical analysis was performed using Stata version 10.1 (StataCorp LP, College Station, TX, USA). Quantitative variables were summarized as medians and compared using the Mann-Whitney U test. Categorical variables were presented as proportions and compared using Fisher's exact test. A logistic regression model to identify factors associated with fatality was built, including those factors found to be significant (P<0.05) in the univariate analysis. Exact logistic regression was also used to deal with zero cells in the analysis when required [17] . Logistic regression was used because of its good statistical properties. Sensitivity and specificity of different variables as predictors of death were compared. Receiver operating characteristic (ROC) curves were also used to examine the specificity and sensitivity at different thresholds of the measure. We would consider a variable as a good predictor of death if its sensitivity is not lower than 80% and the specificity is >50%.
Ethical approval was obtained from all relevant ethics committees, including the Multicentre Research Ethics Committee of London. Written informed consent was obtained from study participants when requested by the relevant ethics committee.
Results
A total of 110 patients were included (n=49 with LA), of whom 19 (17%) died as a consequence of the event a median 8 days (IQR 3-16) after diagnosis. However, 16 out of the 19 patients who died had LA, so the case fatality rate among acidotic patients was 33% (16/49 cases). There was no association between age, gender or ethnic background and death ( 
043).
Of the seven fatal patients who were not receiving dideoxynucleosides at the time of the event, three ceased stavudine 4-7 weeks before the event, and four were receiving zidovudine/lamivudine-based combinations and had never been exposed to dideoxynucleosides in the past. Most patients had gastrointestinal (64%) or constitutional symptoms (57%), although no symptoms were reported in 10 (9%) patients. These asymptomatic patients had a median blood lactate of 5.8 mmol/l (range 5.1-7.3).
A sensitivity analysis using different threshold values for blood lactate as a dichotomous variable was conducted. Fitting the same model adjusted by age, concurrent opportunistic infections and current CD4 + T-cell count, but varying the blood lactate threshold, a value of 7 mmol/l resulted in the highest model likelihood (Table 2) . ROC curves were constructed to assess the appropriateness of different thresholds of blood lactate or bicarbonate to construct binary predictors of death. There was no difference between the area under the curve calculated for these variables. Levels of lactate ranging from 7.27 to 8.1 mmol/l, as well as levels of bicarbonate ranging between 11 and 14 mmol/l, appear to be good choices for cutoff in predicting death.
The model presented in Table 3 shows a significant and independent association between lactate levels of 7-10 mmol/l and fatality when compared with <7 mmol/l (OR 6.27 [95% CI 1. .0-13.95] for fatal and non-fatal patients, respectively). Similarly, no differences were seen in the direction of the association between any of the variables analysed and death when the analysis was restricted to patients from centres where lactate was routinely measured compared to those in centres where it was not (AA-P et al., data not shown).
No symptom-free patient was acidotic or died, so absence of symptoms perfectly predicted survival. No association was found between the presence of any specific symptom and fatality. When the analysis was limited to symptomatic patients there was no change on the magnitude of the association between factors independently associated with death in the general model (AA-P et al., data not shown). To explore the association between the presence of symptoms and death, an exact logistic regression model was fitted [17] . After adjusting by blood levels of lactate and bicarbonate, concurrent OI, CD4 + T-cell count and age, the estimated association between symptoms and fatal outcome was inconclusive (OR 0.39 [95% CI 0.03-infinity]) because our study included too few asymptomatic patients (Table 4) .
As shown in Table 5 , the specificity of a model combining blood lactate >7 mmol/l and bicarbonate <12 mmol/l was 90% to predict fatality, although its sensitivity was 37%. Blood lactate >7 mmol/l showed a specificity of 60% but with a sensitivity of 84%. Similarly, bicarbonate <18 mmol/l showed a very high sensitivity (90%) with a specificity similar to the figure calculated for lactate >7 mmol/l (54%). On the contrary, the sensitivity of blood bicarbonate <12 mmol/l was 42%.
Discussion
Our study showed an overall fatality rate of 17% but, in patients with demonstrated LA, the rate was 33%.
This was similar to the 33% reported in a Spanish case-series and a retrospective cohort study in Soweto, South Africa, where 7 of the 23 (30%) patients with LA died [2, 13] . Slightly lower rates have been reported in recent studies in Uganda and Cape Town, South Africa where 5 of 24 (21%) cases and 11 of 73 (15%) cases of LA died, respectively [14, 18] .
Two small European cohort studies of symptomatic HL showed that only those who eventually developed LA died [19, 20] . It has been suggested that HL may progress to LA if the offending drug is not discontinued [9, 21] . There is little evidence of HL leading to death unless acidosis is also present. None of the 44 cases of symptomatic HL included in a South African study died [2] . In our study, the exact cause of death of the three patients with HL who died within 2 weeks after diagnosis was not recorded and, therefore, we cannot exclude the possibility of other conditions contributing to the outcome. However, some patients in the HL group had blood lactate levels >10 mmol/l, which have been proposed as suggestive of acidosis [8] . Therefore, some of the HL cases in whom blood pH was not measured may have had acidosis at the time of diagnosis.
Most reports of HL/LA in HIV-infected adults include only patients with suggestive symptoms, but our study shows that patients with confirmed HL (blood lactate >5 mmol/l) can be asymptomatic or have symptoms mild enough to not be reported. By contrast, in a Lactic acidaemia definition as indicated in [8] . The new combined model included lactate >7 mmol/l and bicarbonate <12 mmol/l. NPV, negative predictive value; PPV, positive predictive value.
prospective cohort study John et al. [22] found that all patients (5/349) who ever had blood lactate levels >5 mmol/l were clearly symptomatic. It has been suggested that asymptomatic HL may be due to spurious results from an inappropriate blood collection technique [23] . However, it is unlikely that incorrect management of blood samples would produce consistent blood lactate levels >5 mmol/l. Nevertheless, because of the retrospective nature of this study, it is not possible to exclude the possibility of mild symptoms not being reported and/or not being recorded in patient records. Two previous studies have found lactate levels >10 mmol/l as independently associated with death in patients with HL/LA [13, 15] . Our study included a higher number of fatalities than those previously reported, and this provides greater power to assess the association between lactate and fatality. In our study, blood lactate >7 mmol/l was independently associated with death. Although the lactic acidaemia definition [8] showed a sensitivity of 100% (95% CI 82-100) for fatality, its specificity was quite poor as 94% of nonfatal cases also had lactate >5 mmol/l. The sensitivity of lactate >7 mmol/l was 84% but had a better specificity than the lactic acidaemia definition (60%). Adding bicarbonate <12 mmol/l to lactate >7 mmol/l increased its specificity to 90% but decreased its sensitivity from 90% to 40%. Compared with the lactic acidaemia definition, a combined definition based on blood lactate (>7 mmol/l) and bicarbonate (<12 mmol/l), as well as blood lactate >7 mmol/l alone, showed a better specificity for fatality (Table 5) . Although most patients with HL/LA would recover after stopping exposure to the offending drugs, those with more severe episodes (that is, those more likely to die) may benefit from more intense monitoring and additional interventions. Given the cost implications of intense follow-up and management for severe cases, a definition with the highest possible specificity would be ideal because it would reduce the number of false positives to a minimum. In that context, blood lactate >7 mmol/l appeared to be a good predictor for fatality with high sensitivity and 60% specificity.
Stead et al. [5] , who reported 12 fatalities in 89 cases in a South African retrospective cohort analysis, reported a significant association between low blood bicarbonate levels and death. In our study, after adjusting for other variables and potential confounders, the association between blood bicarbonate <12 mmol/l and fatality was evident (OR 10.02 [95% CI 1.33-75.65]) when compared to those patients with bicarbonate levels >18 mmol/l. However, according to our results, bicarbonate <12 mmol/l may be a weak predictor for fatality on its own because of its poor sensitivity. Nevertheless, based on the calculated sensitivity and specificity for fatality (90% and 54%, respectively), it appears that bicarbonate <18 mmol/l may be as good as lactate >7 mmol/l in predicting death. Furthermore, there was some evidence suggesting a possible association between bicarbonate ranging between 12 and 18 mmol/l and fatality (OR 5.82 [95% CI 0.76-44.89]) in the multivariate analysis.
In this study, concurrent OI were independently associated with fatal outcome. No association between fatality and markers of immunosuppression has been reported in previous studies. However, it has also been suggested that acute bacterial infections may induce LA in patients with high baseline blood lactate levels [21] . As we did not record the precise cause of death, we cannot exclude the possibility that concurrent infections played an important role in inducing LA leading to death in patients with previously compensated HL.
Although a number of studies have suggested an increased risk for HL/LA in non-White populations compared to White ones [2, 4, 16, 24] , we found no association between ethnic background and death. Similarly, fatality rates reported in African studies are not higher than those found in Europe [2, 4, 13, 14] . Therefore, one could assume that even if some ethnic groups may be at higher risk for HL/LA when exposed to dideoxynucleosides, the outcome of their event is not necessarily worse than for white Europeans.
Most of the proposed classifications for blood lactate disorders in HIV-infected patients have used a threshold of 10 mmol/l to either make a diagnosis of severe HL [10] or classify a case of 'lactic acidaemia' regardless of the presence of symptoms [8, 25] . However, in the light of results of our study, it may be pertinent to consider a different threshold value, as patients with blood lactate >7 mmol/l might be at a significant risk of dying. Although we have found asymptomatic patients with confirmed blood lactate >5 mmol/l, our data cannot be used to assess accurately the association between the presence of symptoms and fatality, as none of the asymptomatic patients died and only 9% of the included patients were symptom free. However, the association between lactate or bicarbonate levels and death appeared to remain at the same level predicted by the logistic regression model, even after adjusting for the presence of symptoms in the exact logistic regression model (Table 4) .
Using specific threshold values of blood lactate and/or bicarbonate levels would require regular monitoring of blood samples. A targeted approach might be appropriate in those individuals particularly at risk for HL/LA, such as female patients, obese or overweight individuals, those with advanced HIV-induced immunosuppression, elderly patients and, probably, those from non-White ethnic origin who are receiving dideoxynucleoside-based ART [1, 2, 5, 16] . Point-of-care blood lactate analysers have been successfully used in resource-limited settings to monitor patients on dideoxynucleoside-based therapies [26, 27] . In addition, in some middle-income countries, standard bicarbonate is measured in patients with symptoms suggestive of HL [5] .
Our study has some limitations. Patients were mostly from well-resourced countries; therefore, our results may be limited in their generalizeability to resourcelimited settings where the dideoxynucleosides (stavudine and didanosine) are still widely used. However, our cases were diagnosed between 1997 and 2003 when dideoxynucleosides were frequently used in wellresourced countries, the fatality rates reported by African investigators do not differ from rates reported in European studies and ethnic origin was not associated with fatality in our analysis. Patients were diagnosed with HL/LA and followed-up in different centres which had diverse policies; therefore, the availability of data was not uniform across the study population. Blood lactate was not routinely monitored in all participant centres; therefore, some patients may have been tested for lactate because of the presence of symptoms, exposure to dideoxynucleosides or presence of another medical condition. However, we could not find any major difference between patients routinely tested for lactate and those who were not, except for a stronger association between fatality and concurrent OI in patients not routinely tested for lactate. We did not collect data on cause of death, therefore we cannot exclude the contribution of other factors to the outcome. Finally, patients exposed to dideoxynucleosides tend to develop HL/ LA within few months, so long-term exposure to ART on the cohorts where patients were extracted from may impact HL/LA incidence rate. However, because patients were identified retrospectively with non-limitation on calendar period, the age of the cohort should have no major impact on incidence. Our study could not assess the effect of BMI on fatality.
In summary, patients with confirmed severe HL can be asymptomatic. In addition, blood bicarbonate <12 mmol/l, lactate >7 mmol/l and concurrent OI appeared to be associated with death in patients with HL/LA. Blood lactate >7 mmol/l and perhaps bicarbonate <18 mmol/l can predict death and may help to identify patients who may benefit from more intense monitoring.
